Table 1.
Clinical and pathologic characteristics of 392 men diagnosed with cancer in the Rotterdam branch of the European Randomized Study of Screening for Prostate Cancer and treated with radical prostatectomy
| Characteristics | Results |
|---|---|
| Screening round, no. (%) | |
| 1 | 270 (69) |
| 2 | 122 (31) |
| Age, yr, median (IQR) | 64 (61–67) |
|
| |
| Clinical characteristics | |
|
| |
| Clinically significant disease, no. (%) | 260 (66) |
| Positive DRE, no. (%) | 139 (35) |
| Biopsy cores, no. (%) | |
| 6 | 259 (66) |
| 7 | 133 (34) |
| Positive cores, no. (%) | |
| 0 | 2 (1) |
| 1 | 129 (33) |
| 2 | 104 (27) |
| 3+ | 157 (40) |
| Biopsy Gleason score, no. (%) | |
| ≤6 | 289 (74) |
| 7 | 87 (22) |
| ≥8 | 16 (4) |
| Kallikrein panel, ng/ml, median (IQR) | |
| Total PSA | 4.54 (3.39–6.64) |
| Free PSA | 0.80 (0.54–1.10) |
| Intact PSA | 0.44 (0.32–0.63) |
| hK2 | 0.069 (0.047–0.10) |
| Clinical stage, no. (%) | |
| <T2b | 330 (84) |
| ≥T2b | 61 (16) |
| Prostate volume, ml, median (IQR) | 37 (29–49) |
| Maximum percentage of cancer in any one biopsy core, median (IQR) | 8 (3–19) |
| Cancerous tissue, mm, median (IQR) | 6 (2–13) |
| Benign tissue, mm, median (IQR), n = 387 | 64 (52–71) |
|
| |
| Pathologic characteristics | |
|
| |
| Pathologically significant disease, no. (%) | 261 (67) |
| Tumor volume, cm3, median (IQR) | 0.6 (0.2–1.3) |
| Tumor volume ≥0.5 cm3, no. (%) | 219 (56) |
| Pathologic Gleason score, no. (%), n = 389 | |
| ≤6 | 250 (64) |
| 7 | 123 (32) |
| ≥8 | 16 (4) |
| Pathologic stage ≥T2b, no. (%) | 296 (76) |
IQR = interquartile range; DRE = digital rectal examination; PSA = prostate-specific antigen; hK2 = kallikrein-related peptidase 2.
Clinically indolent disease on biopsy was defined using the Epstein criteria: serum PSA <10, biopsy Gleason score <6, clinical stage T2a or lower, three or fewer positive cores, ≥50% of any one core involved with tumor; pathologically insignificant disease was defined as small tumor volume (<0.5 cm3) confined to the prostate with no focal or established extracapsular extension with Gleason grade ≥3.